Treatment of new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome with tocilizumab in a child and a young adult
Epilepsia · 2023-06 · 64 (6)
DOI: 10.1111/epi.17591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, online erschienen am 05.04.2023. Verfasst von Marie-Laure Girardin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Intensive Care Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Hauptthemen laut MEDLINE: Status Epilepticus, Drug Resistant Epilepsy, Encephalitis, Epileptic Syndromes. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
New onset refractory status epilepticus (NORSE) is a rare and devastating condition occurring in a previously healthy patient. It is called febrile infection‐related epilepsy syndrome (FIRES) when preceded by a febrile infection. It often leads to intensive care treatment, including antiseizure drugs in combination with anesthetic agents, and sometimes ketogenic diet. The mortality rate is high, and severe epileptic and neuropsychiatric sequelae are usually observed. Based on the possible role of neuroinflammation, intravenous immunoglobulin, corticosteroids, and immunomodulatory treatment (anti‐IL1, IL6) can be added. We describe here a child and a young adult with FIRES, both treated with tocilizumab. We observed a rapid positive response on the status epilepticus and good tolerance, but different neurological outcomes for our two patients. Further prospective studies may be necessary both to confirm the efficacy and the safety of this promising treatment and to optimize the immunomodulatory strategy in FIRES/NORSE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Intensive Care Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Department of Intensive Care Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Department of Neuropediatrics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Reference Center for Rare Epilepsies, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Department of Neurology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
ORCID-Profile: Anne De Saint-Martin
Zitieren
APA
Girardin, M. L., Flamand, T., Roignot, O., Abi Warde, M. T., Mutschler, V., Voulleminot, P., Guillot, M., Dinkelacker, V., & De Saint-Martin, A. (2023). Treatment of new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia, 64(6). https://doi.org/10.1111/epi.17591
Vancouver
Girardin ML, Flamand T, Roignot O, Abi Warde MT, Mutschler V, Voulleminot P, et al. Treatment of new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia. 2023;64(6). doi:10.1111/epi.17591
BibTeX
@article{Girardin2023,
author = {Girardin, Marie-Laure and Flamand, Thomas and Roignot, Ombeline and Abi Warde, Marie-Thérèse and Mutschler, Véronique and Voulleminot, Paul and Guillot, Max and Dinkelacker, Vera and De Saint-Martin, Anne},
title = {Treatment of new onset refractory status epilepticus/febrile infection‐related epilepsy syndrome with tocilizumab in a child and a young adult},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {6},
doi = {10.1111/epi.17591}
}
EUVIMED